Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance
Authors
Keywords
ESCC, Mouse avatar, Afatinib, Src family kinases, Acquired resistance
Journal
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-30
DOI
10.1186/s13045-018-0651-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma
- (2018) Jingyuan Wang et al. CANCER LETTERS
- Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
- (2018) Zuhua Chen et al. Journal of Hematology & Oncology
- Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization
- (2018) Jianling Zou et al. Journal of Translational Medicine
- Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
- (2017) Russell D. Petty et al. JOURNAL OF CLINICAL ONCOLOGY
- Current status and perspectives of patient-derived xenograft models in cancer research
- (2017) Yunxin Lai et al. Journal of Hematology & Oncology
- Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
- (2017) Zuhua Chen et al. Journal of Translational Medicine
- Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer
- (2017) Mohan Suntharalingam et al. JAMA Oncology
- Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommonepidermal growth factor receptormutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
- (2016) Eri Banno et al. CANCER SCIENCE
- Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study
- (2016) Jing Huang et al. Journal of Thoracic Oncology
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries
- (2015) María José Domper Arnal WORLD JOURNAL OF GASTROENTEROLOGY
- Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer
- (2015) Yan Zhu et al. Scientific Reports
- Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries
- (2015) Hongmei Zeng et al. Thoracic Cancer
- Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer
- (2014) T. Yoshida et al. CLINICAL CANCER RESEARCH
- Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
- (2014) Susan J Dutton et al. LANCET ONCOLOGY
- Identification of genomic alterations in oesophageal squamous cell cancer
- (2014) Yongmei Song et al. NATURE
- Genetic landscape of esophageal squamous cell carcinoma
- (2014) Yi-Bo Gao et al. NATURE GENETICS
- Genomic and molecular characterization of esophageal squamous cell carcinoma
- (2014) De-Chen Lin et al. NATURE GENETICS
- Esophageal Carcinoma
- (2014) Anil K. Rustgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Oesophageal carcinoma
- (2013) Arjun Pennathur et al. LANCET
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
- (2013) Thomas Crosby et al. LANCET ONCOLOGY
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
- (2011) Siyuan Zhang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
- (2010) David H. Ilson et al. CANCER
- Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
- (2009) S. Lorenzen et al. ANNALS OF ONCOLOGY
- The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2009) J. K. Rho et al. MOLECULAR CANCER RESEARCH
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started